Media headlines about Uroplasty (NASDAQ:UPI) have been trending somewhat positive this week, according to Accern. The research group identifies positive and negative news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Uroplasty earned a media sentiment score of 0.10 on Accern’s scale. Accern also assigned press coverage about the medical device company an impact score of 45.0209640620018 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Shares of Uroplasty (NASDAQ:UPI) remained flat at $$1.22 during midday trading on Friday. The company has a market cap of $27.68, a P/E ratio of -4.07 and a beta of -1.26. Uroplasty has a 52-week low of $1.05 and a 52-week high of $4.05.
ILLEGAL ACTIVITY WARNING: “Uroplasty (UPI) Receiving Somewhat Favorable Press Coverage, Study Shows” was first posted by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this piece of content can be read at https://sportsperspectives.com/2018/03/11/uroplasty-upi-receiving-somewhat-favorable-press-coverage-study-shows.html.
Cogentix Medical, Inc (Cogentix Medical) is a medical device company. The Company is engaged in the design, development, manufacturing and marketing of products for endoscopy with its product lines featuring a visualization system and sterile disposable microbial barrier, known as EndoSheath technology, providing users with endoscope turnover.
Receive News & Ratings for Uroplasty Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uroplasty and related companies with MarketBeat.com's FREE daily email newsletter.